We demonstrated that Pramlintide therapy resulted in decreased HIF-1α in the TME, again suggesting that Pramlintide can help alter the TME from one that is immunosuppressive to one that supports immune cell mediated anti-tumor activity. Here, HIF1A is linked to neoplasm.